Alimera Sciences, Inc. (ALIM) Trading NaN Higher

Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) shot up NaN during trading on Thursday . The company traded as high as $1.32 and last traded at $0.00. 539,733 shares changed hands during trading, an increase of Infinity from the average session volume of 0 shares.

A number of research firms recently weighed in on ALIM. ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Zacks Investment Research lowered shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Friday, August 4th. Finally, Cowen and Company set a $3.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.38.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million for the quarter, compared to the consensus estimate of $10.20 million. The business’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the company posted ($0.17) EPS. sell-side analysts predict that Alimera Sciences, Inc. will post -0.2 EPS for the current fiscal year.

Several large investors have recently modified their holdings of ALIM. JW Asset Management LLC increased its holdings in shares of Alimera Sciences by 15.6% in the 2nd quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 130,000 shares during the last quarter. KCG Holdings Inc. increased its holdings in shares of Alimera Sciences by 127.0% in the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 43,977 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Alimera Sciences by 24.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 35,200 shares during the last quarter. 37.20% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/03/alimera-sciences-inc-alim-trading-nan-higher.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

What are top analysts saying about Alimera Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alimera Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit